Skip to content
Dosage GuideResearch Reference

Apelin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Apelin. All information is for educational purposes only.

Quick Answer

Apelin dosage is still largely investigational. Clinical trials have primarily used intravenous infusions of pyroglutamyl apelin-13 at 10-300 nmol/min. Subcutaneous apelin analogs are under development to improve bioavailability and duration of action, but no standard dosing exists for this route.

→ Apelin Benefits→ Apelin Side Effects→ Full Apelin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 10-300 nmol/min (IV infusion of pyroglutamyl apelin-13)

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Heart Failure (clinical research)

10-300 nmol/minContinuous IV infusion
Duration

Hours to days (acute studies)

Administered intravenously under close hemodynamic monitoring. Pyroglutamyl apelin-13 is the typical isoform used.

Pulmonary Arterial Hypertension (clinical research)

Investigational (MM07 analog)Unknown
Duration

Ongoing trials

Synthetic apelin analogs are being developed for PAH to overcome the short half-life of native apelin.

Metabolic Enhancement (preclinical)

Variable (animal studies)Variable (animal studies)
Duration

Variable (animal studies)

Animal studies suggest potential benefits for insulin sensitivity and glucose uptake, but no human dosing has been established.

Timing & Frequency

Due to the short half-life of native apelin peptides, continuous intravenous infusion is required for sustained effects. Apelin analogs with improved stability are under development for less frequent dosing.

Cycle Guidance

Continuous infusion is used in clinical settings. Apelin analogs may allow for intermittent dosing strategies pending further research.

Reconstitution Reference

Quick reference for reconstituting Apelin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeN/A (typically supplied as a solution for IV infusion)
BAC Water VolumeN/A
Concentration & DrawVariable, depending on formulation
StorageFollow manufacturer’s instructions for storage of IV solutions.
StabilityFollow manufacturer’s instructions for stability of IV solutions.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the typical dosage of apelin in clinical trials?
Clinical trials for heart failure have used intravenous infusions of pyroglutamyl apelin-13 at rates of 10-300 nmol/min. The infusion rate is adjusted based on the patient’s hemodynamic response.
Are there oral forms of apelin available?
No, native apelin peptides are not orally bioavailable due to rapid degradation. Research is focused on developing protease-resistant apelin analogs for subcutaneous or potentially oral administration, but these are still investigational.
How is apelin administered in research studies?
In clinical research, apelin is typically administered as a continuous intravenous infusion. Animal studies may use bolus injections or infusions, depending on the research question.
What is the best time to administer apelin?
Since native apelin requires continuous infusion, timing is not a primary consideration. For apelin analogs, dosing schedules will depend on their pharmacokinetic properties and the specific therapeutic application.

References

  1. 1
    Apelin in heart failure: current knowledge and future perspectives.(2014)PubMed ↗
  2. 2
    Pharmacokinetics and pharmacodynamics of synthetic apelin analogue MM07 in healthy subjects and patients with pulmonary arterial hypertension.(2019)PubMed ↗
  3. 3
    Apelin and its receptor APJ: structure, function, distribution, and involvement in disease.(2014)PubMed ↗

Last updated: 2026-02-19